Pathology Grand Rounds
Mark Sulkowski, M.D.
Presented 04/01/2004
Assistant Professor
Johns Hopkins Medical Institutions
"Hepatitis C in HIV Infected Persons"

AMP 2003 Presentations: Karin Berg MD, MS

Real-time PCR Comparison Chart

A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter.

Claudin 3 and 4 expression in gastric and esophageal cancer

New FLT3 Trial

Transcription Mediated Amplification Animation

bDNA Methodology Animation

New FLT3 Trial

Download Requisition Form (pdf)

A new trial of the FLT3 inhibitor, CEP701 in AML patients is scheduled to begin at Johns Hopkins in December 2003. Contacts for this important trial:

Principal Investigator:

B. Doug Smith, MD
Kimmel Cancer Center
Cancer Research Bldg. 246
1650 Orleans St.
Baltimore, MD 21231
Study Coordinator:

Tianna Dauses
Johns Hopkins Cancer Research Bldg.
1650 Orleans St.
Baltimore, MD 21231
410-502-9690 - Fax

FLT3 testing for the CEP701 trial and as a prognostic indicator in AML is available at the Johns Hopkins Molecular Diagnostics Lab. Click here for contact information.

For more information on the FLT3 mutation test developed at The Johns Hopkins University School of Medicine by Dr. Kathleen Murphy, see:

Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay. J Mol Diagn. 2003 May;5(2):96-102.
PubMed Abstract

Homepage | Site Info | Contact Us | Links | Search

Pathology Homepage
Copyright © 1999 - 2005 The Johns Hopkins University
All rights reserved. No part of this website may be reproduced in any
form or by any means or incorporated into any information retrievel system,
electronic or mechanical, without the written permission of JHU.